NCT05417906CompletedPhase 2
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
Investigating the Blood Eosinophil Count as a Biomarker to Guide Systemic Corticosteroid Treatment in Hospitalized Exacerbations of Asthma: a Randomized, Controlled, Open-label, Noninferiority Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Asthma attacks which are moderate-to-severe are typically treated with corticosteroids, but the optimal treatment duration is unknown and treatment responses can be variable. Inadequate treatment may compromise recovery, but increased exposure to corticosteroids is, in turn, associated with drug-related adverse effects. There is a need for a biomarker to guide duration of corticosteroid treatment in asthma attacks. One such candidate biomarker is the blood eosinophil count, which may predict steroid-responsiveness. We hypothesize that the blood eosinophil count can potentially be used as a biomarker to guide the duration of corticosteroids in moderate-to-severe asthma attacks. This study will recruit individuals hospitalized for asthma attack. Participants will be randomized to standard care or blood-eosinophil guided systemic corticosteroid therapy. Subjects in the standard arm will receive oral corticosteroids for a total of 5 days. Subjects in the blood-eosinophil guided arm will receive oral corticosteroids for a total of 5 days if admission eosinophil count is ≥ 0.300 x 10\^3/µL, and receive 3 days of oral corticosteroids if the admission blood eosinophil is \< 0.300 x 10\^3/µL. The rate of treatment failure will be compared between these two groups.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- First submitted
- 29 May 2022
- Start date
- 2 Jun 2022
- Primary completion date
- 19 May 2024
- Lead sponsor
- Changi General Hospital
- Diseases
- Asthma
- NCT number
- NCT05417906
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 110
- From 2 Jun 2022 to the primary completion date, 19 May 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant pneumonia
- Other concomitant respiratory conditions e.g. chronic obstructive pulmonary disease, bronchiectasis
- Subjects who are already on an investigational drug or has been participating in another clinical study with an investigational product within the last 6 months
Other illness
- Eosinophilia due to other known causes (eosinophilic granulomatosis and polyangiitis, parasitic infections, malignancy)
Other
- Admission to high-dependency/intensive care unit, or requirement for invasive/noninvasive mechanical ventilation
- Those on anti-IL5 or anti-IL5R treatment
- Pregnant subjects
- Subjects deemed by investigators to have a life expectancy of \< 12 months (any cause)
- Prisoners
Who the study is looking for
- Age ≥ 21 years old
- Admitted for acute exacerbation of asthma and have received ≤ 3 days of systemic corticosteroids
- Have a had a blood eosinophil count (as part of routine clinical care) drawn before administration of systemic corticosteroid
- Have not taken SCS within 7 days prior to presentation to hospital
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Changi General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.